Drug trial results show significant weight loss of approximately 25% in participants
Shattering Myths with Jillian Michaels: The New Weight-Loss Miracle Drug
Get ready to drop some pounds, folks! Celebrity fitness guru Jillian Michaels spills the tea on America's obesity crisis and the future of weight loss with an experimental medication named amycretin. In an exclusive chat with 'Fox & Friends', Jillian dives deep into the link between carbs and our expanding waistlines, and the push to ban junk food from food stamps.
But what's really about to revolutionize the weight loss game is this dazzling new cure-all - amycretin! Developed by Novo Nordisk, this bad boy replicates two hunger hormones – amylin, which governs appetite and creates a sensation of fullness, and glucagon-like peptide 1 (GLP-1), the same hormone used in Ozempic and Wegovy to suppress appetite and skyrocket insulin production.
Martin Holst Lange, executive vice president and head of development at Novo Nordisk, expressed their excitement, saying, "Amycretin is the first treatment to harness the two distinct biological pathways stimulated by amylin and GLP-1 in a single molecule."
In a study involving overweight or obese adults, researchers discovered that participants who received weekly injections of amycretin shed more weight than those who were given a placebo. Those fortunate enough to get the highest doses (up to 60 mg) lost a staggering 24.3% of their body weight in 36 weeks, while the placebo group managed a mere 1.1% decrease.
Preliminary phase 1 trials of the oral (pill) form of amycretin have shown it to be both safe and non-axious, with an "observed reduction in body weight" compared to placebo. A daily dose of amycretin led to approximately 10% weight loss, whereas doubling the dose resulted in 13% weight reduction.
Researchers praised amycretin for its ability to bypass the dreaded weight-loss plateau, meaning users could continue to shed pounds as long as they keep popping these magical pills.
The latest findings on amycretin were presented at the American Diabetes Association conference in Chicago on June 22, where they were also published in the Lancet medical journal.
Martin Holst Lange stated, "We are delighted with the promising results of amycretin and the feedback from regulatory authorities and are thrilled to advance both subcutaneous and oral versions of this molecule into phase 3 development for weight management."
Be ready for those GI symptoms, though! Similar to other GLP-1s, the most common side effects of amycretin are gastrointestinal – such as nausea, vomiting, and loss of appetite. But don't worry, experts stress that these side effects are generally mild to moderate, and escalate with more frequent doses.
Obesity is a tricky beast, and while initial weight-loss results are promising, experts warn us that more studies are needed to ensure therapeutic benefits consistently outweigh the potential risks, especially with long-term administration. Dr. Christine Ren-Fielding, director and chief of bariatric surgery at the NYU Langone Weight Management Program, previously emphasized that these treatments are not a one-size-fits-all solution, and a comprehensive, long-term approach is vital in managing the condition.
In the coming months, Novo Nordisk plans to prepare for phase 3 trials of the medication, in both oral and injectable forms, for the treatment of obesity. Tune in to continue following this groundbreaking research!
Melissa Rudy is a health editor at our website Digital, and you can send her at [email protected] for all your weight loss tips and tricks.
- The potential revolution in weight loss could come from a new medication called amycretin, developed by Novo Nordisk, which replicates two hunger hormones and promises significant weight loss.
- There's promising research suggesting that amycretin, when administered through weekly injections, can lead to significant weight loss, with some participants losing 24.3% of their body weight in 36 weeks.
- Apart from its potential for weight management, amycretin may have implications for overall health and wellness, as it is also associated with improved nutrition and management of medical conditions such as diabetes.
